Curtis Lockshin, Ph.D.
Dr. Lockshin currently serves as the Chief Scientific Officer of Xenetic Biosciences, Inc., a biopharmaceutical company focused on the development of novel oncology therapeutics. Prior to Xenetic, Dr. Lockshin served as the Chief Technical Officer of VBI Vaccines, Inc., where he was the Chief Executive Officer of SciVac Therapeutics, Inc. until its acquisition by VBI in July 2016. Dr. Lockshin also held the role of Vice President of Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO’s R&D units. He initially began his career as a scientist with Sepracor Inc. (now Sunovion Pharmaceuticals Inc.) and eventually became the research director responsible for the strategy and operations of Sepracor’s new leads initiative. Dr. Lockshin holds a S.B. degree in Life Sciences and a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.